bioAffinity Technologies (BIAF) Cost of Revenue (2022 - 2025)

bioAffinity Technologies (BIAF) has reported Cost of Revenue for 4 consecutive years, with $900126.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Cost of Revenue fell 42.38% year-over-year to $900126.0; the TTM figure through Dec 2025 stood at $4.2 million (down 29.36% YoY), while the FY2025 annual figure was $4.2 million, down 29.36% from the prior year.
• Cost of Revenue declined to $900126.0 in Q4 2025 per BIAF's latest filing, from $942211.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.7 million in Q4 2023 and bottomed at $87.0 in Q1 2023.
• Historically, Cost of Revenue has averaged $796775.0 across 4 years, with a median of $942211.0 in 2025.
• Annual changes were most pronounced in 2024 — Cost of Revenue surged 1808452.87% — and 2025, when it tumbled 42.38%.
• bioAffinity Technologies' Cost of Revenue stood at $175.0 in 2022, then soared by 951248.0% to $1.7 million in 2023, then fell by 6.17% to $1.6 million in 2024, then sank by 42.38% to $900126.0 in 2025.
• Business Quant data shows BIAF's Cost of Revenue at $900126.0 in Q4 2025, $942211.0 in Q3 2025, and $1.0 million in Q2 2025.